BioSpace News Archive

Deals

Promore Pharma AB (publ) Interim report January – March 2019

Promore Pharma’s most important task is to develop new products aiming to improve the quality of life for patients with difficult-to-treat wounds and various types of scarring, primarily following surgery.

May 21, 2019
·
3 min read
Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019

Promore Pharma AB held its AGM on Tuesday, 21 May 2019.

May 21, 2019
·
3 min read
Deals

Merck Buys Peloton Therapeutics in $2.2 Billion Deal

Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.

May 21, 2019
·
3 min read
·
Mark Terry
Drug Development

Boehringer Ingelheim Lands Positive Results in Lung Disease Trial

Germany-based Boehringer Ingelheim announced that its SENSCIS Phase III clinical trial met its primary endpoint, which was reduction in the annual rate of decline in forced vital capacity.

May 21, 2019
·
2 min read
·
Mark Terry
Drug Development

Shares of BioCryst Fall After Phase III HAE Drug Underwhelms Investors

Despite hitting endpoints in the late-stage trial, BioCryst’s BCX7353 results do not stack up against Takeda’s Takhzyro, which was approved last year.

May 21, 2019
·
2 min read
·
Alex Keown
Job Trends

More Hacks Inevitable in Pharma Industry, Cybersecurity Expert Says

Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.

May 21, 2019
·
3 min read
·
Alex Keown
Biotech Beach

Accelerating Development of Non-Opioid Pain Medicines

Neil Singla, Chief Executive Officer of Lotus Clinical Research, Chaired the fourth annual American Pain Society Conference on Analgesic Trials (APS-CAT)

May 21, 2019
·
3 min read
Deals

Athera raises 55 million SEK in new share issue

Biotech company Athera announce the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from the Sciety network of investors.

May 21, 2019
·
2 min read
Business

David Jaffray, Ph.D., Named Chief Technology and Digital Officer

Joins MD Anderson from University Health Network/Princess Margaret Cancer Centre

May 21, 2019
·
8 min read
Ophthalmology: Horus Pharma distributes ILUVIEN® in France

Horus Pharma, an independent laboratory specialized in ophthalmology, announces that it is now making ILUVIEN® available to French patients. ILUVIEN is owned by Alimera Sciences, Inc. (US).

May 21, 2019
·
4 min read